Loading
Heart Failure / Amiloride / Bendroflumethiazide · Phase 1 Trial
ClinicalTrials.gov · September 8, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1 mechanistic trial registered to investigate diuretic resistance in heart failure by examining sodium handling and urinary biomarkers in response to combination diuretic therapy. No results are reported in this registry record; the study is actively recruiting. The evidence cannot yet be evaluated.
Phase 1, Interventional, Randomized, Crossover, Triple masking, Other purpose. Heart Failure; age from 18 Years. Intervention: Placebo/ Amiloride; Placebo/ Bendroflumethiazide; Bendroflumethiazide/ Amiloride. Compared with: Placebo/ Placebo — Placebo Comparator. n = 50. 1 site: United States.
This is a Phase 1 mechanistic trial registered to investigate diuretic resistance in heart failure by examining sodium handling and urinary biomarkers in response to combination diuretic therapy. No results are reported in this registry record; the study is actively recruiting. The evidence cannot yet be evaluated.
Efficacy, safety data, and effect sizes for any outcome are not provided.
This mechanistic study may clarify why some heart failure patients become resistant to diuretics, but clinical utility depends on downstream translation. Results are not yet available.
Phase 1 mechanistic study in heart failure with surrogate endpoints (sodium handling, urinary biomarkers) and no results yet reported in this registry record.
As stated by the source record.
Quoted from the source exactly as published.
This mechanistic study may clarify why some heart failure patients become resistant to diuretics, but clinical utility depends on downstream translation. Results are not yet available.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05753059). This is a study registration, not published results. Lead sponsor: Yale University. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 50 participants (ESTIMATED). Conditions: Heart Failure. Interventions: DRUG: Placebo; DRUG: Amiloride; DRUG: Bendroflumethiazide. Primary outcome measures: Change in peak FENa from bumetanide monotherapy to bumetanide plus combination therapy , 21 days; Change in distal sodium reabsorption , 21 days; Correlation between distal sodium reabsorption and uEV pendrin/CD9 , 21 days. Brief summary: Randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.